# Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal

> **NCT04694612** · PHASE3 · UNKNOWN · sponsor: **Nepal Health Research Council** · enrollment: 676 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Favipiravir
- **DRUG:** Placebo
- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT04694612
- **Lead sponsor:** Nepal Health Research Council
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-05-31
- **Target enrollment:** 676 (ESTIMATED)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04694612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04694612, "Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04694612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*